All results
2 results for single arm open label multicenter study evaluating long term safety tolerability and
-
First-In-Human Study of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This study is an international, multi-center, study of Pompe disease patients that are currently receiving enzyme-replacement therapy (ERT). The purpose of…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
u-STOP LVAD Bleed
This is a Phase I, single ascending dose, first in human, open-label, non-controlled, dose-escalation trial that will investigate intravenous infusions of…
- Ages
- 18 Years - 80 Years
- Sexes
- All